{"id":"azd9496-variant-a","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT02780713"],"aliases":[],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"AZD9496 Variant A is a variant of the experimental medication AZD9496, which is being studied in a clinical trial for breast cancer. The study, NCT02780713, is a Phase I trial that aims to evaluate the pharmacokinetic and safety profile of AZD9496 Variant A in healthy subjects.","brandName":"AZD9496 Variant A","companyId":"astrazeneca","mechanism":{"target":"Estrogen receptor (ER)","novelty":"","modality":"Small molecule","drugClass":"","explanation":"AZD9496 is a selective estrogen receptor degrader (SERD) that binds to estrogen receptors and promotes their degradation. By eliminating estrogen receptors from cancer cells, it blocks estrogen-driven tumor growth. The oral formulation offers potential advantages over injectable SERDs.","oneSentence":"AZD9496 Variant A selectively binds to and degrades estrogen receptors, blocking estrogen signaling in cancer cells.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123723,"model":"claude-sonnet-4-5-20250929"},"companyName":"AstraZeneca","competitors":[{"name":"fulvestrant","brand":"Faslodex","company":"AstraZeneca","rationale":"Injectable SERD for ER-positive breast cancer"},{"name":"elacestrant","brand":"Orserdu","company":"Stemline Therapeutics","rationale":"Oral SERD approved for ER-positive breast cancer"},{"name":"giredestrant","brand":null,"company":"Roche","rationale":"Investigational oral SERD for ER-positive breast cancer"}],"description":"AZD9496 Variant A is an investigational oral selective estrogen receptor degrader (SERD) developed by AstraZeneca for the treatment of estrogen receptor-positive breast cancer. It is being evaluated in early-phase clinical trials as a potential alternative to existing endocrine therapies.","genericName":"AZD9496 Variant A","indications":{"approved":[{"status":"investigational","condition":"ER-positive breast cancer","patientPopulation":"Adult, advanced or metastatic"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}